Additionally, NM blocks kallikrein to diminish downstream effects, such as inhibiting brdykinin-mediated inflammation—a therapeutic pathway for sepsis and a potential mechanism for mitigating inflammation during cardiopulmonary bypass (CPB) (He et al., 2024). Here, KLK4 is linked to Sepsis.